InsidersTradesSigma
Follow the Actinium Pharmaceuticals, Inc. share price and the full management transaction log of the company, a listed equity based in United States. Shares are quoted on the US market, under the supervision of SEC (Form 4). Market capitalisation: €2.2bn. The latest transaction was reported on 20 August 2025 (Retenue fiscale). Among the most active insiders: SETH SANDESH. All data is openly available.
Analysts rate Actinium Pharmaceuticals, Inc. Strong Buy (bullish), based on 12 analysts. Average price target: US$59.30.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
2 of 2 declarations
Actinium Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing targeted therapies for cancer treatment. It employs innovative approaches based on radioimmunotherapy.